Market Access News | pharmaphorum

News

NHS saving £300m with Humira biosimilar deal

The NHS is to save £300 million after striking deals with several manufacturers of low cost biosimilars of AbbVie’s Humira inflammatory diseases drug.

News

Paid medicine. Cost of treatment. Isolated 3D image

New UK drug pricing deal promises faster medicines access

The UK government has reached a new five-year medicines pricing deal with the pharma industry to replace the almost 60-year-old Pharmaceutical Price Regulation Scheme (PPRS).

News

Novartis/Spark's sight gene therapy approved in EU

Spark Therapeutics’ gene therapy for a rare inherited sight disorder, Luxturna has been approved in Europe, but there was still no word on price from marketing partner Novartis.

News

Pfizer to hike prices of 41 drugs despite Trump criticism

Pfizer plans to raise the prices of 41 prescription drugs in January, despite falling foul of President Trump, who criticised the company’s stance on costs earlier this summer.

News

Pfizer hit by UK Supreme Court ruling on Lyrica patent

Pfizer has lost its protracted patent battle in the UK for big-selling drug Lyrica, potentially exposing it to claims for hundreds of millions of pounds from the NHS.

News

Vertex told to reveal CF drug price, as MPs begin inquiry

UK politicians could go public with the price of Vertex's cystic fibrosis drug Orkambi, if the company does not strike a deal giving NHS patients access by the end of the month.

NHS saving £300m with Humira biosimilar deal

New UK drug pricing deal promises faster medicines access

Novartis/Spark's sight gene therapy approved in EU

Pfizer to hike prices of 41 drugs despite Trump criticism

Pfizer hit by UK Supreme Court ruling on Lyrica patent

Vertex told to reveal CF drug price, as MPs begin inquiry

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks